Available option
10mg
Lyophilised powder
- Strength
- 10mg
- Format
- Lyophilised powder
Bear Biotech catalogue
PE-22-28
Spadin-derived TREK-1 channel research peptide
- TREK-1 channel
- Neuronal excitability
- Preclinical neurobiology
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is PE-22-28?
PE-22-28 is a short spadin-derived peptide studied as a potent inhibitor of the TREK-1 potassium channel. Preclinical research has examined neuronal excitability, neurogenesis, synaptogenesis and mouse behavioural models. There is no established human therapeutic evidence.
Preclinical in-vitro and mouse research; no established human therapeutic evidence.
Research focus
Key research areas
PE-22-28 research: a compact TREK-1 channel inhibitor
PE-22-28 is a seven-amino-acid analogue derived from spadin research and designed to inhibit the TREK-1 potassium channel. Evidence remains preclinical. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- TREK-1 channel
- Neuronal excitability
- Preclinical neurobiology
Representative primary research
Representative research
Research focuses on TREK-1 channel inhibition, peptide stability, behavioural models, neurogenesis and synaptogenesis.
- Shortened Spadin Analogs / PE-22-28 ↗ In vitro and mouse preclinical study; it does not establish a human therapeutic outcome.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- PE-22-28
- Research category
- Spadin-derived TREK-1 channel research peptide
- Evidence position
- Preclinical in-vitro and mouse research; no established human therapeutic evidence.
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
Why is the TREK-1 channel central to PE-22-28 research?
PE-22-28 research examines TREK-1-channel modulation and neuronal excitability in preclinical neurobiology models.
Which neuronal-excitability endpoints are measured in PE-22-28 models?
TREK-1 and neuronal-excitability studies measure cellular or behavioural endpoints in defined systems. These findings do not establish a human neurological treatment.
What evidence boundary follows from PE-22-28’s preclinical status?
PE-22-28 evidence is limited to preclinical in-vitro and mouse research. No established human therapeutic evidence is available.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.